Literature DB >> 8649787

cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.

E Duprez1, J R Lillehaug, T Naoe, M Lanotte.   

Abstract

We analysed the expression of retinoid receptors and PML in relation to the morphology of PML-containing nuclear bodies (PODs) in maturation sensitive (NB4) and resistant subclones (NB4-R1 and R2) of the promyelocytic NB4 cell line. The basal level of RARalpha, RXRalpha and PML mRNA and protein were roughly the same in the three cell lines. While NB4 and NB4-R1 cells express comparable amounts of PM-RARalpha mRNA and 120 kDa protein, NB4-R2 cells despite normal mRNA levels the 120 kDa protein was not detectable. In NB4-R2 cells however, two novel PML-related entities of 65 kDa and 85 kDA were detected with a anti-PML antibody, in addition to the two PML isoforms of 78 and 97 kDa found in any NB4 cells. Despite the 120 kDa PML-RARalpha defect, NB4-R2 cells show micropunctuated nuclear bodies typical of APL cells. Contrasting with NB4 cells, neither NB4-R1 cells which express PML-RARalpha, nor NB4-R2 cells lacking the 120 kDa PML-RARalpha reorganised nuclear bodies (PODs) in response to RA. Importantly, in RA-primed NB4-R1 cells, a secondary event triggered by cAMP restored PODs, concomitant to maturation. This indicates that the recovery of nuclear bodies in APL is dissociated from the early action of RA in cell maturation. Finally, the key finding of this work is that cAMP signalling ultimately determines the recovery of nuclear bodies associated to cell maturation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649787

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.

Authors:  Rihab Nasr; Hugues de Thé
Journal:  Int J Hematol       Date:  2010-05-11       Impact factor: 2.490

2.  Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins.

Authors:  J Zhu; M Gianni; E Kopf; N Honoré; M Chelbi-Alix; M Koken; F Quignon; C Rochette-Egly; H de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

3.  Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.

Authors:  Percy Luk Yeung; Natalia G Denissova; Cara Nasello; Zhanna Hakhverdyan; J Don Chen; Mark A Brenneman
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

4.  Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies.

Authors:  M H Koken; A Reid; F Quignon; M K Chelbi-Alix; J M Davies; J H Kabarowski; J Zhu; S Dong; S Chen; Z Chen; C C Tan; J Licht; S Waxman; H de Thé; A Zelent
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

Review 5.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.

Authors:  Hugues de Thé; Zhu Chen
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

6.  Interpreting clinical assays for histone deacetylase inhibitors.

Authors:  Nadine Martinet; Philippe Bertrand
Journal:  Cancer Manag Res       Date:  2011-05-09       Impact factor: 3.989

7.  cFos mediates cAMP-dependent generation of ROS and rescue of maturation program in retinoid-resistant acute promyelocytic leukemia cell line NB4-LR1.

Authors:  Jean-Luc Carrier; Pasha Javadi; Emilie Bourrier; Céline Camus; Evelyne Ségal-Bendirdjian; Aïda Karniguian
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.